keryx biopharmaceuticals inc

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 60.3% HIGHER; announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the FDA for the treatment of multiple myeloma.

In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 98.6% HIGHER; At ASCO yesterday, Keryx announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Click here for the full report.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 52.8% HIGHER; reports Q1 EPS of $0.01, 9 cents better than the analyst estimate of ($0.08) and compared to a loss of $0.79 in the same quarter last year.

Revenue for the quarter was $3.3 million, versus the consensus of $320K. Lear Corporation (NYSE: LEA) 20% LOWER; reports Q1 loss of $3.42, versus the analyst estimate of ($1.73).

Revenue for the quarter was $2.2 billion, versus the consensus of $2.15 billion. Power Medical Intervention, Inc.